Eden Biodesign and the University of Birmingham develop therapeutic candidate for the treatment of autoimmune diseases
02-Aug-2007
Dr David Blackbourn commented: "Working with Eden Biodesign will allow us to advance our understanding of the therapeutic potential of this drug candidate; clinical applications for this novel therapy could range from autoimmune diseases such as rheumatoid arthritis to asthma and allergy. We are delighted to have Eden Biodesign contribute to the vOX2 programme at the state of the art facility in Liverpool."
Most read news
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.